Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Nitric oxide synthase, inducible | 0.0065 | 0.8159 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0074 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0484 | 0.0484 |
Chlamydia trachomatis | sulfite reductase | 0.0046 | 0.3805 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0074 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0074 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0065 | 0.8159 | 0.8159 |
Treponema pallidum | flavodoxin | 0.0028 | 0 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0065 | 0.8159 | 0.8159 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0037 | 0.1841 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0074 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0028 | 0 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0074 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0028 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0074 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0074 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0074 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0046 | 0.3805 | 0.3805 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0074 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0028 | 0 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0037 | 0.1964 | 0.0151 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0074 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0074 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0065 | 0.8159 | 0.8159 |
Giardia lamblia | Hypothetical protein | 0.0065 | 0.8159 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0484 | 0.0484 |
Brugia malayi | FAD binding domain containing protein | 0.0046 | 0.3805 | 0.3805 |
Brugia malayi | hypothetical protein | 0.003 | 0.0484 | 0.0484 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0074 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0037 | 0.1841 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0484 | 0.0484 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0074 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0074 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0046 | 0.3805 | 0.2407 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0028 | 0 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0074 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0484 | 0.0484 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0074 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0484 | 0.0484 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0484 | 0.0484 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0074 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0028 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0074 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0074 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0484 | 0.0484 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0074 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0074 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0484 | 0.0484 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.